Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
University of L'Aquila
With
Novartis
Age
25–50
Sex
FEMALE
Healthy volunteers
Not accepted
You may be eligible if
Women aged 25 to 50 years
Chronic or episodic migraine with or without aura diagnosed according to the International Classification of Headache Disorders - 3rd edition
Receiving a first prescription of erenumab for migraine prevention according to the Summary of Product Characteristics and local reimbursement criteria
At least 1 year from migraine onset
Provided informed consent
You may not be if
Headache other than migraine
Prior exposure to erenumab or other monoclonal antibodies targeting CGRP or its receptor
Use of any migraine preventive treatment in the last 60 days or 5 half-lives or 4 months if ever treated with botulinum toxin A
Pregnant or nursing
Body Mass Index \<18 or \>30 Kg/m2
Heavy smoking (more than 20 cigarettes per day)
Myocardial infarction, stroke, transient ischemic attack, unstable angina, or coronary artery bypass surgery or other revascularization procedures within 12 months prior to first visit
Illicit drug abuse
Major psychiatric disorders
Infective or inflammatory diseases
Any chronic medication prescribed for indications different from migraine within 60 days before study initiation
